Glaukos Stock Surges 32% to a Record: Sales Jump 58%

Glaukos stock surged about 32% on Thursday, October 29, 2026, heading for a record close after the eye-care device maker reported sales up 58% and raised its full-year outlook far above Wall Street expectations. The move put the shares on track for their largest one-day percentage gain since August 2018, according to Dow Jones Market Data cited by Barron's.

What happened

Glaukos shares climbed about 30% to $236.64 in Thursday trading, after closing at $181.43 on Wednesday. Market data later showed the stock near $239, up roughly 32% on the day. The rally started in after-hours trading on Wednesday, when the company released its third-quarter results, and it accelerated once the regular session opened.

The headline numbers were well ahead of forecasts. Third-quarter net sales jumped 58% year over year to a record $211 million, blowing past analyst expectations of about $168 million. Adjusted earnings came in at $0.47 per share, compared with expectations for a loss of about $0.10 per share. Zacks reported the same sales figure, $211.03 million, and said revenue beat its consensus estimate by about 25%, while earnings of $0.47 per share beat a consensus forecast for a loss of $0.12 per share. On a statutory basis, the company also swung to about $2 million in net income, reversing a loss of $16.2 million in the same quarter a year earlier.

The guidance raise that changed the story

The bigger surprise was what management said about the future. Glaukos raised its 2026 net sales guidance to between $775 million and $785 million, up sharply from a previous range of $680 million to $700 million. Analysts tracked by FactSet had been looking for about $691.7 million for the year, so the new midpoint sits well above the consensus that investors had been using.

The company then went further, introducing preliminary 2027 net sales guidance of $1 billion. That figure implies another increase of roughly 28% over the revised 2026 midpoint, and it is the number behind the headline that Glaukos is now aiming at a billion dollars in annual sales far sooner than the market had expected.

Why it is blowing up

Three things combined to make this a viral earnings story. First, the beat was large on both sales and earnings, not marginal. Second, the guidance raise was unusually big for a single quarter — a jump of about $90 million at the midpoint for 2026, plus an entirely new $1 billion target for 2027. Third, the stock's reaction fits a pattern: Barron's noted that Glaukos shares had already risen by double digits after each of its previous three earnings reports, so traders were primed for a big move, and this report delivered a bigger one.

Analysts moved quickly on Thursday. BTIG, Stifel and Wells Fargo all reiterated bullish calls on the stock while lifting their price targets past $200, according to Barron's. One Benzinga report put Wells Fargo's new target at $226. Those upgrades added momentum during the session, even as the new targets were in some cases below where the stock was already trading after the surge.

What Glaukos does

Glaukos is a medical device company focused on eye diseases. Its name comes from the Greek word that later evolved into the medical term glaucoma, and glaucoma remains a core focus, alongside corneal disorders and retinal diseases. That mix is why a single quarter matters so much for the valuation: investors are pricing not just current device sales, but how fast newer eye treatments can scale toward that $1 billion revenue goal.

What to watch next

The $1 billion figure for 2027 is preliminary guidance, not a contract, and its credibility depends on product launches and reimbursement. Coverage of the results noted that the investment case now hinges in part on whether the Epioxa launch can sustain rapid growth while proposed Medicare coverage restrictions create uncertainty around future use of iDose TR, one of the company's glaucoma treatments. If sales keep tracking toward the new 2026 range in the next quarter, the record close will look like a re-rating. If growth slows, Thursday's 32% jump sets a high bar to defend. Either way, Glaukos has moved from a small-cap device name to one of the biggest earnings stories of the week.

Sources: Barron's, Zacks, MarketBeat, Business News Today

FAQ

Why did Glaukos stock surge 32% today?

Glaukos beat expectations by a wide margin, with sales up 58% to $211 million versus about $168 million expected, and it raised 2026 guidance while introducing a $1 billion sales target for 2027.

What were Glaukos's Q3 2026 earnings?

The company reported adjusted earnings of $0.47 per share, versus expectations for a loss of about $0.10 per share, on record net sales of $211.03 million.

What is Glaukos's new guidance?

Management raised 2026 net sales guidance to $775 million to $785 million, from $680 million to $700 million previously, and gave preliminary 2027 guidance of $1 billion.

Is the $1 billion 2027 target guaranteed?

No. It is preliminary guidance, and analysts note it depends on product launches such as Epioxa and on reimbursement, including proposed Medicare coverage changes affecting iDose TR.